LungLife AI, Inc. (LLAI)
LSE LSE Primary Summary
LLAI Chart
LungLife AI, Inc. (LLAI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has LungLife AI, Inc. ever had a stock split?
LungLife AI, Inc. Profile
| - Industry | - Sector | Dr. Paul Pagano Ph.D. CEO | LSE Exchange | U5500L104 CUSIP |
| United States Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
LungLife AI, Inc. is a pioneering diagnostic company focused on leveraging artificial intelligence (AI) technology to advance clinical diagnostic solutions for lung cancer. Operating within the United States and the People's Republic of China, the company is at the forefront of developing innovative approaches to enhance lung cancer diagnostics. Initially known as Cynvenio Biosystems, Inc., it underwent a name change to better reflect its strategic focus and rebranded as LungLife AI, Inc. in May 2019. Founded in 2009, the company is headquartered in Thousand Oaks, California, positioning itself as a key player in the fight against lung cancer through its advanced diagnostic technologies.
Products and Services
LungLB: At the heart of LungLife AI's product lineup is LungLB, a cutting-edge blood-based test designed to improve the accuracy of lung cancer diagnostics. This innovative test is developed to stratify cancerous and benign lung nodules as identified by a CT scan, offering a non-invasive alternative to traditional diagnostic methods. By leveraging advanced AI algorithms, LungLB aims to enhance the precision and reliability of lung nodule classification, thereby facilitating early detection and treatment of lung cancer. This product embodies the company's commitment to integrating AI technology into healthcare to provide better outcomes for patients.
